MRK: MK-0616: Next gen cholesterol pill?

MRK: Ahead of the first of 3 upcoming 2025 oral PCSK9 CORALreef phase III results in 2Q25, our in-depth analysis suggests a favourable outcome for MRK’s oral MK-0616, in both FH (2Q25) and secondary prevention (2Q25 & 3Q25) ahead of consensus. However, phase III trial design leaves us cautious in its ability to break into the lucrative primary prevention market.

MRK